Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer
research and therapy. These range from the identification of the first specific chromosomal …

AProtein kinase targeted. A number of these molecules are broad-spectrum kinase
inhibitors. BStaurosporine class represents examples of broad-spectrum kinase inhibitors …

In tumor cells from virtually all patients with chronic myelogenous leukemia, the Philadelphia
chromosome, a fusion of chromosomes 9 and 22, directs the synthesis of the P210 bcr/abl …

Cytogenetics is the study of chromosome morphology, structure, pathology, function, and
behavior. The field has evolved to embrace molecular cytogenetic changes, now termed …

The search for genetic damage in neoplastic cells now occupies a central place in cancer
research. Diverse examples of such damage are in hand, and they in turn hint at …

The P210bcr/abl protein is associated with virtually every case of human chronic
myelogenous leukemia. Unlike the related P160gag/v-abl oncogene product of Abelson …

The twenty-first century is beginning with a sharp turn in the field of cancer therapy.
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …

The history of tyrosine kinase oncogenes can be traced to 1911 when Peyton Rous, of the
Rockefeller Institute, demonstrated that a chicken tumor could be wx transplanted using a …

Imatinib as a paradigm of targeted therapies Page 10 Imatinib as a Paradigm of Targeted
Therapies Brian J. Druker Howard Hughes Medical Institute, Cancer Institute, Oregon Health …

Signal transducer and activator of transcription (STAT) 5 is constitutively activated in
BCR/ABL-expressing cells, but the mechanisms and functional consequences of such …